Skip to content

Remimazolam Reduces Emergence Delirium in Preschool Children Undergoing Laparoscopic Surgery by Sevoflurane Anesthesia

Remimazolam Reduces Emergence Delirium in Preschool Children Undergoing Laparoscopic Surgery by Sevoflurane Anesthesia: a Double-blinded Randomized Clinical Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04621305
Enrollment
120
Registered
2020-11-09
Start date
2020-11-21
Completion date
2021-11-30
Last updated
2021-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergence Delirium

Keywords

remimazolam, emergence delirium

Brief summary

Emergence delirium (ED) is a manifestation of acute postoperative brain dysfunction that occurs with a relatively high frequency after pediatric anesthesia. The incidence varies depending on the diagnostic criteria used and the combination of administered anesthetic drugs. The use of sevoflurane has been identified as one of the most important risk factors. In the investigators' study,the researchers conducted the current study to investigate whether remimazolam can reduce incidence of ED.

Detailed description

One hundred twenty children aged 1-6 years old were randomly allocated into three equal groups. Anesthesia is induced with propofol,fentanyl and rocuronium. In group P (Placebo group), anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered. In group B (Bolus group), anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered. In group C (continuous infusion group), anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered. Maintain BIS values in the range of 40-60. Recorded the pediatric anesthesia emergence delirium scale (PAED) during the recovery period.

Interventions

OTHERnormal saline

Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered

DRUGBolus Remimazolam

Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.

DRUGContinuous Infusion Remimazolam

Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.

Sponsors

Second Affiliated Hospital of Wenzhou Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to 6 Years
Healthy volunteers
Yes

Inclusion criteria

1. -with American Society of Anesthesiologists (ASA) physical status I or II; 2. -aged 1-6 years; 3. -children with weight for age within the normal range; 4. -were scheduled laparoscopic surgery by sevoflurane anesthesia.

Exclusion criteria

1. -children who had Abnormal liver and kidney function,Cardiovascular or endocrine dysfunction; 2. -allergy or hypersensitive reaction to remimazolam; 3. -with any organ dysfunction; 4. -recently respiratory infection, mental disorder; 5. -other reasons that researchers hold it is not appropriate to participate in this trial.

Design outcomes

Primary

MeasureTime frameDescription
The incidence of emergence deliriumWithin up to 30 minutes after operationThe pediatric anesthesia emergence delirium scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score.pediatric anesthesia emergence delirium scale ≥10 at any time indicates presence of emergence delirium.

Secondary

MeasureTime frameDescription
Pediatric anesthesia emergence deliriumWithin up to 30 minutes after operationThe pediatric anesthesia emergence delirium scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score.
FLACC scaleWithin up to 30 minutes after operationThe FLACC scale consists of fIve items. Each item is scored 0-2 yielding a total between 0 and 10. The degree of pain increased directly with the total score.
End tidal sevoflurane concentrationDuring the preoperative periodEnd tidal sevoflurane concentration at BIS 40-60
Recovery timesUp to 30 minutes after operationThe time from discontinuation of sevoflurane to the first open eye of the children and to achieve aldrete≥9
Number of children with adverse effectsUp to 24 hours including intraoperative, and postoperative periodsNumber of children with adverse effects Bradycardia and/or hypotension need for hemodynamic support Desaturation is defined as Oxygen desaturation \<90% Any adverse effects requiring interventions
Ramsay Sedation Scale scoreWithin up to 30 minutes after operation1. \- The patient is anxious and agitated, restless, or both; 2. \- The patient is cooperative, oriented, and tranquil; 3. \- The patient responds to commands only; 4. \- The patient is asleep and shows a brisk response to a light glabellar tap or loud auditory stimulus; 5. \- The patient is asleep and shows a slow response to a light glabellar tap or loud auditory stimulus; 6. \- The patient is asleep and shows no response to a light glabellar tap or loud auditory stimulus. The degree of sedation increased directly with the total score.

Countries

China

Contacts

Primary ContactHuacheng Liu
huachengliu@163.com18957755138
Backup ContactYuhang Cai
838097626@qq.com18815091585

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026